NYSE:PFE

Pfizer Inc (PFE)

24.10
-0.63 (2.53%)
as of Jun 24, 2026, 7:36:27 pm Market Open.
581 watching
0
Investor Insights
star iconJun 24, 2026, 12:00 am

This summary was created by AI, based on 29 opinions in the last 12 months.

Pfizer Inc (PFE) is facing significant challenges as it navigates a patent cliff and the subsequent impacts on revenue after its COVID-19 vaccine boom. Many analysts express concerns about the lack of earnings momentum and the uncertain prospects for new blockbuster drugs in its pipeline. Despite these challenges, PFE maintains an attractive dividend yield ranging from 6% to 7% that provides a steady income for shareholders. The company's strategy includes cost-cutting measures and acquiring smaller companies to refill its drug development pipeline. However, the stock typically trades at a low price-to-earnings ratio, indicating a lack of confidence in future growth, with multiple experts suggesting a need for patience and a potential wait for positive catalysts to drive price appreciation.

consensus icon
Consensus
Hold
valuation icon
Valuation
Undervalued
review icon
Similar
NVO
BUY
Good short/long term growth potential. Great pipeline.
DON'T BUY
Suspicious of large cap drug companies. High risk industry.
BUY ON WEAKNESS
A little high now. Buy below $40.
TOP PICK
(Was a top pick on Jan 8/01 up 2%) Prefers over Merck. Less patent expiries. In a good position with good pipeline.
BUY
Likes both Pfizer and Merck in pharmaceuticals.
DON'T BUY
Caution. At its FMV.
TOP PICK
Least amount of patent expiry. Have some good new product launches. Good pipeline.
BUY
Always expensive, but a good pipeline. Long term.
BUY
Prefers over Merck. No patent expiries.
PAST TOP PICK
(Was a top pick on Apr 27/00 up 3.3%) Still likes.
TOP PICK
Great pipeline of drugs. Good synergies. Safe play. Price a little high.
BUY
At a good price now. Good pipeline.
DON'T BUY
At fair market value. Now ($45). No room to grow.
TOP PICK
(Was a top pick on Jan 8 down 3%) Still likes. Just bought more. Has the least amount of patent expiries.
TOP PICK
Long term. Strong growth/company.
Showing 856 to 870 of 883 entries